Eli Lilly and Company· @EliLillyandCo · X·· 1 天前AI 评分22
AI 导读
面向HCP的新证据：一项新的间接治疗比较今日在#EASD2026上公布，评估了我们口服GLP-1的最高剂量与另一种口服2型糖尿病药物更高剂量的对比：https://go.lilly.com/gmsarf
正文
New evidence for HCPs: A new indirect treatment comparison, shared today at #EASD2026, evaluated the highest dose of our oral GLP-1 alongside a higher dose of another oral medicine for type 2 diabetes: https://go.lilly.com/gmsarf
来源：Eli Lilly and Company · x.com